公开(公告)号：US10232023B2

公开(公告)日：2019-03-19

申请号：US15441982

申请日：2017-02-24

Applicant: THE UNIVERSITY OF UTAH RESEARCH FOUNDATION

Inventor： Christian Con Yost ,  Guy A. Zimmerman ,  Andrew S. Weyrich

IPC: A61K38/00 ,  A61K38/57 ,  A61K38/17 ,  C07K14/47

Abstract: An isolated and purified peptide, neonatal NET-inhibitory Factor (nNIF), is disclosed. Methods for treatment of and prophylaxis against inflammatory disorders are also disclosed, including methods of treatment of and prophylaxis against inflammatory disorders comprising administering NET-inhibitory peptides (NIPs), which may be a nNIF, a pharmaceutically acceptable salt of a nNIF, a nNIF analog, a pharmaceutically acceptable salt of a nNIF analog, a nNIF-Related Peptide (nNRP), including the nNRP, Cancer-Associated SCM-Recognition, Immune Defense Suppression, and Serine Protease Protection Peptide (CRISPP), a pharmaceutically acceptable salt of a nNRP, a nNRP analog, or a pharmaceutically acceptable salt of a nNRP analog, to an individual.

公开(公告)号：US20170232081A1

公开(公告)日：2017-08-17

申请号：US15441982

申请日：2017-02-24

Applicant: THE UNIVERSITY OF UTAH RESEARCH FOUNDATION

Inventor： Christian Con Yost ,  Guy A. Zimmerman ,  Andrew S. Weyrich

IPC: A61K38/57

CPC classification number: A61K38/57 ,  A61K38/00 ,  A61K38/1709 ,  C07K14/4703 ,  Y02A50/385 ,  Y02A50/387 ,  Y02A50/473

Abstract: An isolated and purified peptide, neonatal NET-inhibitory Factor (nNIF), is disclosed. Methods for treatment of and prophylaxis against inflammatory disorders are also disclosed, including methods of treatment of and prophylaxis against inflammatory disorders comprising administering NET-inhibitory peptides (NIPs), which may be a nNIF, a pharmaceutically acceptable salt of a nNIF, a nNIF analog, a pharmaceutically acceptable salt of a nNIF analog, a nNIF-Related Peptide (nNRP), including the nNRP, Cancer-Associated SCM-Recognition, Immune Defense Suppression, and Serine Protease Protection Peptide (CRISPP), a pharmaceutically acceptable salt of a nNRP, a nNRP analog, or a pharmaceutically acceptable salt of a nNRP analog, to an individual.

公开(公告)号：US20160194365A1

公开(公告)日：2016-07-07

申请号：US14904048

申请日：2014-07-07

Applicant: THE UNIVERSITY OF UTAH RESEARCH FOUNDATION

Inventor： Christian Con Yost ,  Guy A. Zimmerman ,  Andrew S. Weyrich

IPC: C07K14/47 ,  A61K47/48

CPC classification number: A61K38/57 ,  A61K38/00 ,  A61K38/1709 ,  C07K14/4703 ,  Y02A50/385 ,  Y02A50/387 ,  Y02A50/473

Abstract: An isolated and purified peptide, neonatal NET-inhibitory Factor (nNIF), is disclosed. Methods for treatment of and prophylaxis against inflammatory disorders are also disclosed, including methods of treatment of and prophylaxis against inflammatory disorders comprising administering NET-inhibitory peptides (NIPs), which may be a nNIF, a pharmaceutically acceptable salt of a nNIF, a nNIF analog, a pharmaceutically acceptable salt of a nNIF analog, a nNIF-Related Peptide (nNRP), including the nNRP, Cancer-Associated SCM-Recognition, Immune Defense Suppression, and Serine Protease Protection Peptide (CRISPP), a pharmaceutically acceptable salt of a nNRP, a nNRP analog, or a pharmaceutically acceptable salt of a nNRP analog, to an individual.

Abstract translation: 公开了分离和纯化的肽，新生儿NET抑制因子（nNIF）。 还公开了治疗和预防炎症性疾病的方法，包括治疗和预防炎性病症的方法，包括施用可以是nNIF的网络抑制肽（NIP），nNIF的药学上可接受的盐，nNIF类似物 ，nNIF类似物的药学上可接受的盐，nNIF相关肽（nNRP），包括nNRP，癌症相关SCM识别，免疫防御抑制和丝氨酸蛋白酶保护肽（CRISPP），nNRP的药学上可接受的盐 ，nNRP类似物或nNRP类似物的药学上可接受的盐。